PL2643698T3 - Biomarkery do przewidywania skuteczności immunoterapii raka - Google Patents

Biomarkery do przewidywania skuteczności immunoterapii raka

Info

Publication number
PL2643698T3
PL2643698T3 PL11788121.9T PL11788121T PL2643698T3 PL 2643698 T3 PL2643698 T3 PL 2643698T3 PL 11788121 T PL11788121 T PL 11788121T PL 2643698 T3 PL2643698 T3 PL 2643698T3
Authority
PL
Poland
Prior art keywords
biomarkers
predict
effectiveness
cancer immunotherapy
immunotherapy
Prior art date
Application number
PL11788121.9T
Other languages
English (en)
Inventor
Toni Weinschenk
Harpreet Singh
Jens Fritsche
Andrea Mahr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of PL2643698T3 publication Critical patent/PL2643698T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
PL11788121.9T 2010-11-24 2011-11-22 Biomarkery do przewidywania skuteczności immunoterapii raka PL2643698T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41698110P 2010-11-24 2010-11-24
GBGB1021289.2A GB201021289D0 (en) 2010-12-15 2010-12-15 Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
US42365210P 2010-12-16 2010-12-16

Publications (1)

Publication Number Publication Date
PL2643698T3 true PL2643698T3 (pl) 2016-12-30

Family

ID=43567254

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11788121.9T PL2643698T3 (pl) 2010-11-24 2011-11-22 Biomarkery do przewidywania skuteczności immunoterapii raka

Country Status (17)

Country Link
US (2) US8669063B2 (pl)
EP (1) EP2643698B1 (pl)
JP (1) JP6005051B2 (pl)
KR (1) KR20130119453A (pl)
CN (1) CN103384827B (pl)
AU (1) AU2011333819A1 (pl)
BR (1) BR112013012820A2 (pl)
CA (1) CA2818738A1 (pl)
EA (1) EA201390762A1 (pl)
ES (1) ES2592957T3 (pl)
GB (1) GB201021289D0 (pl)
HU (1) HUE030005T2 (pl)
MX (1) MX341734B (pl)
NZ (1) NZ609712A (pl)
PL (1) PL2643698T3 (pl)
SG (1) SG190698A1 (pl)
WO (1) WO2012069462A1 (pl)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS53782B1 (sr) 2008-10-01 2015-06-30 Immatics Biotechnologies Gmbh Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
US9026531B2 (en) * 2012-04-17 2015-05-05 Cerner Innovation, Inc. Associating multiple data sources into a web-accessible framework
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
CN103048453B (zh) * 2012-12-18 2014-11-26 苏州浩欧博生物医药有限公司 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法
MX2016005825A (es) 2013-11-07 2016-12-09 Medial Res Ltd Procedimientos y sistemas para evaluar un riesgo de cancer de pulmon.
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
GB201505585D0 (en) * 2015-03-31 2015-05-13 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers
US20180371550A1 (en) * 2015-07-08 2018-12-27 Children's Hospital Medical Center Loss of transcriptional fidelity leads to immunotherapy resistance in cancers
WO2017011439A1 (en) * 2015-07-13 2017-01-19 Biodesix, Inc. Predictive test for melanoma patient benefit from pd-1 antibody drug and classifier development methods
ES2970865T3 (es) 2015-12-16 2024-05-31 Gritstone Bio Inc Identificación, fabricación y uso de neoantígenos
US11710539B2 (en) 2016-02-01 2023-07-25 Biodesix, Inc. Predictive test for melanoma patient benefit from interleukin-2 (IL2) therapy
CN105624110A (zh) * 2016-02-29 2016-06-01 时宏珍 Hla-a0201限制性抗psa抗原特异性ctl的制备方法
GB201604490D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides combination of peptides for use in immunotherapy against cancers
EP3455631B1 (en) * 2016-05-09 2020-06-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for classifying patients with a solid cancer
WO2018039452A1 (en) * 2016-08-24 2018-03-01 The Wistar Institute Of Anatomy And Biology Methods of treating cancers with chemotherapy with reduced toxicity
CN106198987A (zh) * 2016-08-31 2016-12-07 辽宁迈迪生物科技股份有限公司 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用
KR102379955B1 (ko) 2016-12-08 2022-03-29 이매틱스 바이오테크놀로지스 게엠베하 짝짓기가 향상된 t 세포 수용체
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
WO2018129301A1 (en) * 2017-01-05 2018-07-12 Biodesix, Inc. Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups
WO2018156448A1 (en) 2017-02-21 2018-08-30 The Board Of Regents Of The Uiversity Of Texas System Prediction and treatment of immunotherapeutic toxicity
US10699007B2 (en) * 2017-03-13 2020-06-30 Oracle International Corporation Hybrid univariate/multivariate prognostic-surveillance technique
KR102018006B1 (ko) * 2017-06-02 2019-09-04 이종균 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트
EP4576103A3 (en) 2017-10-10 2025-08-27 Gritstone bio, Inc. Neoantigen identification using hotspots
CN111630602A (zh) 2017-11-22 2020-09-04 磨石肿瘤生物技术公司 减少新抗原的接合表位呈递
US12094587B2 (en) 2018-03-29 2024-09-17 Biodesix, Inc. Apparatus and method for identification of primary immune resistance in cancer patients
WO2019195823A1 (en) * 2018-04-06 2019-10-10 The Board Of Regents Of The University Of Texas System Prediction and treatment of immunotherapeutic toxicity
CN108624650B (zh) * 2018-05-14 2022-04-29 乐普（北京）医疗器械股份有限公司 判断实体瘤是否适合免疫治疗的方法和检测试剂盒
CN110885886B (zh) * 2018-09-07 2023-04-07 华中科技大学同济医学院附属协和医院 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法
KR102159538B1 (ko) * 2019-01-11 2020-09-24 충남대학교 산학협력단 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
EP3948286B1 (en) * 2019-03-28 2025-07-23 F. Hoffmann-La Roche AG Cancer prognosis
CN111257563B (zh) * 2020-01-22 2022-08-23 广州泛恩生物科技有限公司 Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途
EP4168802A4 (en) * 2020-06-21 2025-03-19 Oncohost Ltd HOST SIGNATURES THAT PREDICTE IMMUNOTHERAPY RESPONSE
US20230314408A1 (en) * 2020-07-02 2023-10-05 Gopath Laboratories Llc Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer
JP6985567B1 (ja) * 2020-07-10 2021-12-22 積水メディカル株式会社 Ｔａｒｃを含有する組成物、及びｔａｒｃの保存安定性向上方法
JP6979149B1 (ja) * 2020-07-10 2021-12-08 積水メディカル株式会社 Ｔａｒｃを含有する組成物、及びｔａｒｃの保存安定性向上方法
CN113219173A (zh) * 2021-05-11 2021-08-06 中南大学湘雅医院 Sh2b1在肺癌诊断中的应用
CN113462776B (zh) * 2021-06-25 2023-03-28 复旦大学附属肿瘤医院 m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用
CN115058440B (zh) * 2022-06-08 2023-08-15 郑州轻工业大学 催化合成天然蔗糖酯的工程菌及其构建方法和应用
CN115612737A (zh) * 2022-08-03 2023-01-17 皖南医学院第一附属医院（皖南医学院弋矶山医院） 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用
CN118072954A (zh) * 2024-02-06 2024-05-24 江南大学附属医院 一种基于trp评分系统的胃癌免疫治疗反应预测方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPM322393A0 (en) 1993-12-24 1994-01-27 Austin Research Institute, The Mucin carbohydrate compounds and their use in immunotherapy
JP3490893B2 (ja) * 1998-06-02 2004-01-26 富士レビオ株式会社 胃癌の診断方法
WO2005098446A2 (en) * 2004-03-31 2005-10-20 The Johns Hopkins University Biomarkers for ovarian cancer
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
WO2007056012A2 (en) * 2005-11-02 2007-05-18 Bayer Healthcare Llc Methods for prediction and prognosis of cancer, and monitoring cancer therapy
US20090035801A1 (en) * 2005-12-27 2009-02-05 Power3 Medical Products, Inc. Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer
DK2848938T3 (da) * 2006-04-24 2017-11-13 Critical Care Diagnostics Inc Evaluering af effektiviteten af en behandling hos et individ baseret på st2- niveauer
AT504231A1 (de) * 2006-10-03 2008-04-15 Hans Dr Loibner Prädiktive parameter
HUE032379T2 (en) * 2007-07-27 2017-09-28 Immatics Biotechnologies Gmbh Composition of tumour-associated peptides and related anti-cancer vaccine
GB0718167D0 (en) * 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
EP2080812A1 (en) * 2008-01-18 2009-07-22 Transmedi SA Compositions and methods of detecting post-stop peptides
EP2105740A1 (en) * 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Biomarkers for monitoring or predicting the treatment of cancer
WO2010003773A1 (en) 2008-06-16 2010-01-14 Siemens Medical Solutions Diagnostics Gmbh Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
WO2010076322A1 (en) 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
US20100240546A1 (en) * 2009-03-20 2010-09-23 Samuel Chun Lap Lo Use of biomarkers for the diagnosis and prognosis of lung cancer

Also Published As

Publication number Publication date
US9389235B2 (en) 2016-07-12
JP2014500493A (ja) 2014-01-09
US20140234347A1 (en) 2014-08-21
MX341734B (es) 2016-08-31
NZ609712A (en) 2015-05-29
CA2818738A1 (en) 2012-05-31
MX2013005762A (es) 2013-08-12
WO2012069462A1 (en) 2012-05-31
ES2592957T3 (es) 2016-12-02
GB201021289D0 (en) 2011-01-26
CN103384827B (zh) 2016-06-08
US8669063B2 (en) 2014-03-11
EA201390762A1 (ru) 2013-09-30
SG190698A1 (en) 2013-07-31
BR112013012820A2 (pt) 2017-05-09
HUE030005T2 (en) 2017-04-28
KR20130119453A (ko) 2013-10-31
EP2643698A1 (en) 2013-10-02
JP6005051B2 (ja) 2016-10-12
EP2643698B1 (en) 2016-06-22
US20120128702A1 (en) 2012-05-24
AU2011333819A1 (en) 2013-05-23
CN103384827A (zh) 2013-11-06

Similar Documents

Publication Publication Date Title
PL2643698T3 (pl) Biomarkery do przewidywania skuteczności immunoterapii raka
SMT201600135B (it) Nuovi inibitori della s-nitrosoglutatione riduttasi
SMT201700109B (it) Inibitori di istone demetilasi
EP2758080A4 (en) ANTICANCER IMMUNOTHERAPY
EP2536854A4 (en) PERSONALIZED TUMOR BIOMARKERS
EP2625292A4 (en) KREBSBIOMARKER
EP2596467A4 (en) Credit risk mining
FR2966037B3 (fr) Ensemble balai-eponge
IL252163A0 (en) Lung cancer biomarkers and uses thereof
PL3296319T3 (pl) Sposoby leczenia nowotworu jelita grubego
IL221719A (en) Biomarkers for theranostics
ES2638522T8 (es) Procedimientos para detectar cáncer
HUE064982T2 (hu) Csövek építése
IL229319A0 (en) Biomarkers for lung cancer
LT3284754T (lt) Antikūnai prieš cd38
SMT201600370B (it) Complessi chelati di oligonucleotidi
IL220084A (en) Tumor tissue based biomarkers for bevacizumab combination therapies
BR112013011752A2 (pt) curtimento não metálico
IL228636A0 (en) Biomarkers for predicting sensitivity to cancer treatments
EP2775844A4 (en) BIOMARKER FOR THE RESPONSE TO NAE INHIBITORS
ZA201703026B (en) Biomarkers for the prediction of incident cancer
EP2638355A4 (en) TOOL REVOLVER ARRANGEMENT
BR112012019494A2 (pt) dispositivo elétrico
BR112013000371A2 (pt) invólucro
EP2558859A4 (en) MICRO ARRAYS